시간 외 거래: 1.19

Aclaris Therapeutics Inc (ACRS)

Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스

Aclaris Therapeutics Inc (ACRS)

Aclaris Therapeutics Inc 주식(ACRS)의 최신 뉴스

Stifel Maintains Aclaris Therapeutics (ACRS) Buy Recommendation - MSN

An analyst sees good growth prospects for Aclaris Therapeutics Inc (ACRS) – Sete News - SETE News

Short Interest in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Rises By 19.2% - Defense World

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Short Interest Up 19.2% in April - MarketBeat

Aclaris Therapeutics Inc (ACRS)'s highs and lows: A closer look at its stock price fluctuations – US Post News - US Post News

Balance Sheet Breakdown: Aclaris Therapeutics Inc (ACRS)'s Debt-to-Equity and Long-Term Debt/Eq Ratios – DWinneX - The Dwinnex

Equities Analysts Offer Predictions for Aclaris Therapeutics, Inc.'s FY2024 Earnings (NASDAQ:ACRS) - MarketBeat

Foghorn Therapeutics Inc. (FHTX) Soars 13.1%: Is Further Upside Left in the Stock? - Yahoo Lifestyle UK

Investing in Aclaris Therapeutics (NASDAQ:ACRS) three years ago would have delivered you a 943% gain - Yahoo Lifestyle UK

Monaco Asset Management SAM Takes $1.03 Million Position in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - MarketBeat

Leerink Partnrs Comments on Aclaris Therapeutics, Inc.'s Q2 2024 Earnings (NASDAQ:ACRS) - MarketBeat

Earnings Update: Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance

Aclaris Therapeutics Announces Q1 2024 Financial Performance: Corporate Updates Shift Focus to Novel, Capital ... - MyChesCo

Stifel Maintains Aclaris Therapeutics (ACRS) Buy Recommendation - MSN

Aclaris Therapeutics First Quarter 2024 Earnings: Beats Expectations - Simply Wall St

Stock Performance Spotlight: Aclaris Therapeutics Inc (ACRS) Ends the Day at 1.22, Down by -8.96 – DWinneX - The Dwinnex

Aclaris Therapeutics Announces Q1 2024 Financial Performance: Corporate Updates Shift Focus to Novel, Capital ... - MyChesCo

Aclaris Therapeutics to Announce Q1 Financial Results and Host Conference Call - MSN

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript - Insider Monkey

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Q1 2024 Earnings Call Transcript - Yahoo Finance

Aclaris Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com South Africa

Aclaris Therapeutics Inc earnings beat by $0.04, revenue topped estimates - Investing.com India

Aclaris Therapeutics (ACRS) Reports Q1 Loss, Tops Revenue Estimates

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - GlobeNewswire

Aclaris Therapeutics Reports First Quarter 2024 Financial Results and Provides a Corporate Update - Yahoo Finance

Investing in Aclaris Therapeutics Inc (ACRS): What You Must Know – Knox Daily - Knox Daily

Aclaris: Q1 Earnings Snapshot - Milford Mirror

BioCryst Pharmaceuticals (BCRX) Reports Q1 Loss, Tops Revenue Estimates

Aclaris Therapeutics (ACRS) Expected to Beat Earnings Estimates: What to Know Ahead of Q2 Release - Yahoo New Zealand News

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Tops Revenue Estimates - Yahoo Movies UK

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $22.25 Average Price Target from Analysts - MarketBeat

Aclaris Therapeutics, Inc. (NASDAQ:ACRS) Receives $22.25 Average Price Target from Analysts - MarketBeat

ACRS (Aclaris Therapeutics Inc) has impressive results – US Post News - US Post News

Aclaris Therapeutics to Announce First Quarter 2024 Financial Results on May 7, 2024 and to Provide Corporate Update - GlobeNewswire

Aclaris Therapeutics to Announce Q1 Financial Results and Host Conference Call - MyChesCo

BML Capital Management LLC Invests $686000 in Aclaris Therapeutics, Inc. (NASDAQ:ACRS) - Defense World

ACRS Shares Experience Decline in Value – Knox Daily - Knox Daily

Global Dermatological Therapeutics Market Analysis & Forecast 2024-2034 by Drug Class, Application and Region - GlobeNewswire

Are Medical Stocks Lagging Aclaris Therapeutics (ACRS) This Year?

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year?

Is Aclaris Therapeutics (ACRS) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance

Aclaris Therapeutics Inc (ACRS) Stock Has Fallen -4.92% This Week: Buy, Hold, or Sell? - InvestorsObserver

Aclaris Therapeutics, Inc.'s (NASDAQ:ACRS) Shares Climb 25% But Its Business Is Yet to Catch Up - Simply Wall St

Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying

Lumen Technologies And 2 Other Stocks Under $2 Insiders Are Buying - Lumen Technologies (NYSE:LUMN), Acla - Benzinga

Aclaris (ACRS) Upgraded to Buy: Here's Why

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year?

Is Aclaris Therapeutics (ACRS) Outperforming Other Medical Stocks This Year? - Yahoo Finance

Aclaris Therapeutics: A Year of Financial Resilience and Steady Advancements - MyChesCo

Aclaris Therapeutics Full Year 2023 Earnings: Beats Expectations - Yahoo Finance

ACRS과 유사한 종목